# Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

> **NCT05212662** · PHASE2 · WITHDRAWN · sponsor: **Thiogenesis Therapeutics, Inc.**

## Conditions studied

- COVID-19
- COVID-19 Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** TTI-0102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05212662
- **Lead sponsor:** Thiogenesis Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09-27
- **Primary completion:** 2024-09-27
- **Final completion:** 2024-09-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor is not pursuing the COVID-19 indication at this time.
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212662, "Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05212662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*